(Q38739672)

6 September 2017

title

Dinutuximab: A Review in High-Risk Neuroblastoma (English)

1 reference

6 September 2017

Sheridan M Hoy

1

1 reference

6 September 2017

publication date

19 February 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

11

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

247-253

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-016-0420-2

6 September 2017

exact match

0 references

cites work

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Recent advances in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0420-2

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26891967

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26891967

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26891967

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-016-0420-2

1 reference

Dimensions Publication ID

6 September 2017

1012948001

0 references

1 reference